No quarterly revenue total was found in Cognition Therapeutics, Inc.'s SEC filings.
Cognition Therapeutics, Inc. (CGTX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$3.3 million. As of Sep 30, 2026 it held $30.8 million in cash and investments and $489,000 in total debt.
Revenue
—
Net income
$-4.14M
+15.9% vs year-ago quarter
Operating cash flow
$-3.26M
+42.3% vs year-ago quarter
Free cash flow
$-3.26M
-6.1% vs prior quarter
EPS
$-0.04
+33.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
95.10M
+7.7% vs year-ago quarter
Net cash
$30.27M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CGTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Purchase, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1455365
- Former names
- COGNITION THERAPUTICS INC (until Dec 28, 2010)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$7.4M | -$7.7M | -$8.8M | -$13.7M | -$6.4M |
| Net income | -$4.1M | -$3.9M | -$4.6M | -$3.3M | -$4.9M |
| Diluted EPS | -$0.04 | -$0.04 | -$0.05 | -$0.04 | -$0.06 |
| Operating cash flow | -$3.3M | -$3.1M | -$5.5M | -$3.4M | -$5.7M |
| Free cash flow | -$3.3M | -$3.1M | — | — | — |
| Total assets | $34.8M | $38.9M | $36.1M | $48.4M | $43.4M |
| Total liabilities | $5.5M | $5.9M | $6.2M | $14.1M | $6.9M |
| Stockholders' equity | $29.3M | $33.0M | $29.9M | $34.3M | $36.5M |
| Cash and investments | $30.8M | $34.0M | $31.1M | $36.8M | $39.3M |
| Total debt | $489,000 | $511,000 | $271,000 | $331,000 | $380,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Listing notice
|
Nov 5, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 22, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Other events
|
Jun 24, 2026 | Jun 24, 2026 |
All 303 Cognition Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.